MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
Rosa Ayala(Hospital Universitario 12 De Octubre), David Lavie(Hadassah Medical Center), Oriana Esposito, Maan Alwan, Indu Raman(Epworth Hospital), Jesús María Hernández‐Rivas(Universidad de Salamanca), Shodeinde Coker(Bristol-Myers Squibb (United States)), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Palanikumar Ravindran(Bristol-Myers Squibb (United States)), Haifa Kathrin Al‐Ali(University Hospital in Halle), Nieves López‐Muñoz, Vincent Ribrag(Institut Gustave Roussy), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Costas K. Yannakou(Epworth Hospital), Massimiliano Bonifacio(University of Verona), Christopher Tehlirian(Bristol-Myers Squibb (United States)), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Bin Wu(Bristol-Myers Squibb (United States)), Zariana Nikolova(Bristol-Myers Squibb (Switzerland)), Si Tuen Lee-Hoeflich(Bristol-Myers Squibb (United States)), Guan Wang(Bristol-Myers Squibb (United States)), Yu Liu(Bristol-Myers Squibb (United States)), Qian Zhao(Baotou Medical College), Sharmilla Das(Bristol-Myers Squibb (United States)), Adi Shacham Abulafia(Tel Aviv University), Jean‐Jacques Kiladjian(Délégation Paris 5), Jean-Christope Ianotto(Centre Hospitalier Régional Universitaire de Brest), Yulia Volchek(Assaf Harofeh Medical Center)
Cited by 2
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Non-coding recurrent mutations in chronic lymphocytic leukaemia
|Nature|2015|851